Associated Diseases


Variant Type

Biomarker-Directed Therapies

Significance of PD-L1 Expression in Diseases

Non-Small Cell Lung Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Breast Carcinoma +

Gastric Carcinoma +

Cervical Carcinoma +

Malignant Esophageal Neoplasm +

Adenocarcinoma Of The Gastroesophageal Junction +

Malignant Solid Tumor +

Melanoma +

Gastric Adenocarcinoma +

Urothelial Carcinoma +

Squamous Cell Lung Carcinoma +

Non-Squamous Non-Small Cell Lung Carcinoma +

Colorectal Carcinoma +

Renal Cell Carcinoma +

Oropharyngeal Squamous Cell Carcinoma +

Bladder Carcinoma +

Clear Cell Renal Cell Carcinoma +

Hypopharyngeal Squamous Cell Carcinoma +

Laryngeal Squamous Cell Carcinoma +

Oral Cavity Squamous Cell Carcinoma +

Ovarian Carcinoma +

Small Cell Lung Carcinoma +

Cervical Adenocarcinoma +

Cervical Adenosquamous Carcinoma +

Cervical Squamous Cell Carcinoma +

Pancreatic Adenocarcinoma +

Bladder Urothelial Carcinoma +

Breast Adenocarcinoma +

Glioblastoma +

Hepatocellular Carcinoma +

Hodgkin Lymphoma +

Invasive Breast Carcinoma +

Lung Adenocarcinoma +

Merkel Cell Carcinoma +

Non-Hodgkin Lymphoma +

Prostate Adenocarcinoma +

Prostate Carcinoma +

Skin Squamous Cell Carcinoma +

Urethral Urothelial Carcinoma +

Ampulla Of Vater Clear Cell Adenocarcinoma +

Biliary Tract Carcinoma +

Bladder Clear Cell Adenocarcinoma +

Carcinoma Of Unknown Primary +

Carcinosarcoma +

Cervical Clear Cell Adenocarcinoma +

Cholangiocarcinoma +

Clear Cell Adenocarcinoma +

Clear Cell Hepatocellular Carcinoma +

Clear Cell Odontogenic Carcinoma +

Clear Cell Sarcoma Of Soft Tissue +

Clear Cell Sarcoma Of The Kidney +

Clear Cell Squamous Cell Skin Carcinoma +

Colorectal Adenocarcinoma +

Cutaneous Melanoma +

Diffuse Large B-Cell Lymphoma +

Endometrial Carcinoma +

Endometrial Clear Cell Adenocarcinoma +

Esophageal Adenocarcinoma +

Esophageal Carcinoma +

Esophageal Squamous Cell Carcinoma +

Extrahepatic Bile Duct Clear Cell Adenocarcinoma +

Fallopian Tube Clear Cell Adenocarcinoma +

Follicular Lymphoma +

Gallbladder Carcinoma +

Head And Neck Carcinoma +

Hereditary Clear Cell Renal Cell Carcinoma +

Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +

Large Cell Lung Carcinoma +

Large Cell Lung Carcinoma, Clear Cell Variant +

Liver And Intrahepatic Bile Duct Carcinoma +

Lymphoma +

Malignant Mesothelioma +

Malignant Ovarian Clear Cell Tumor +

Mediastinal Large B-Cell Lymphoma +

Mesothelioma +

Mucosal Melanoma +

Multiple Myeloma +

Myelodysplastic Syndromes +

Nasopharyngeal Carcinoma +

Oropharyngeal Carcinoma +

Ovarian Clear Cell Tumor +

Pancreatic Carcinoma +

Pancreatic Ductal Adenocarcinoma +

Peritoneal Malignant Mesothelioma +

Pleural Biphasic Mesothelioma +

Pleural Epithelioid Mesothelioma +

Pleural Mesothelioma, Sarcomatoid Type +

Renal Pelvis Urothelial Carcinoma +

Renal Pelvis And Ureter Urothelial Carcinoma +

Skin Clear Cell Basal Cell Carcinoma +

Squamous Cell Carcinoma Of Unknown Primary +

Tenosynovial Giant Cell Tumor +

Tenosynovial Giant Cell Tumor, Diffuse Type +

Thymic Clear Cell Carcinoma +

Ureter Urothelial Carcinoma +

Urethral Clear Cell Adenocarcinoma +

Uterine Ligament Clear Cell Adenocarcinoma +

Vulvar Clear Cell Hidradenocarcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.